Recent Updates — ARTL

The Securities and Exchange Commission approved a new Nasdaq listing compliance rule requiring listed companies to maintain a minimum market value of listed securities (MVLS) of at least $5,000,000. Artelo Biosciences was among approximately 180 companies initially identified as falling below this threshold. Although a temporary stay on the rule was announced in late July and Nasdaq has proposed modifying its operative date pending SEC review, the company acknowledges potential delisting proceedings if the rule is reinstated without modification. The company intends to monitor developments and may consider raising capital through existing at-the-market equity programs or other corporate actions to regain compliance, though no specific course of action has been committed to. Artelo Biosciences operates in the biotechnology industry, focusing on the development of diagnostic technologies.

At its Annual Meeting of Stockholders on July 17, 2026, Artelo Biosciences, Inc. approved an amendment to its Articles of Incorporation to increase the number of authorized shares of common stock from 166,666,667 to 500,000,000. Shareholders also approved the issuance of more than 20% of issued and outstanding common stock under an Equity Purchase Agreement with Square Gate Capital Master Fund, LLC – Series 5. Additionally, Gregory R. Reyes, Tamara A. Favorito, and Gregory D. Gorgas were re-elected as Class III directors. The company is a biotechnology firm that develops therapeutic candidates for medical conditions.